Clinical Trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Name: Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — clinical trial record (NCT06040541)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Protocol Amendment History 8 amendments

This ClinicalTrials.gov record has been amended 8 times since 2023-09-08; most recent amendment 2026-06-02.

Trial Details

NCT Number	NCT06040541
Lead Sponsor	Revolution Medicines, Inc.
Conditions	Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Enrollment	604 participants
Start Date	2023-09-07
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-03